Clinical Cancer Research Landon Prizes for Basic and Translational Cancer Research Infection and Cancer: Biology, Therapeutics, and Prevention
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Liby, K.
Right arrow Articles by Letterio, J. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Liby, K.
Right arrow Articles by Letterio, J. J.
Clinical Cancer Research Vol. 12, 4288-4293, July 15, 2006
© 2006 American Association for Cancer Research


Cancer Therapy: Preclinical

The Synthetic Triterpenoid CDDO-Imidazolide Suppresses STAT Phosphorylation and Induces Apoptosis in Myeloma and Lung Cancer Cells

Karen Liby1, Nga Voong3, Charlotte R. Williams1, Renee Risingsong1, Darlene B. Royce1, Tadashi Honda2, Gordon W. Gribble2, Michael B. Sporn1 and John J. Letterio3,4

Authors' Affiliations: 1 Dartmouth Medical School and 2 Dartmouth College, Hanover, New Hampshire; 3 National Cancer Institute, Bethesda, Maryland; and 4 Case Western Reserve University School of Medicine, Cleveland, Ohio

Requests for reprints: John J. Letterio, Division of Pediatric Hematology Oncology, Rainbow Babies and Children's Hospital, 11100 Euclid Avenue, Cleveland OH 44106. Fax: 216-844-5431; E-mail: John.Letterio{at}uhhs.com.

Purpose: Excessive activity of the transcription factors known as signal transducers and activators of transcription (STAT) contributes to the development and progression of malignancy in many organs. It is, therefore, important to develop new drugs to control the STATs, particularly their phosphorylation state, which is required for their transcriptional activity.

Experimental Design: Myeloma and lung cancer cells were treated with the new synthetic triterpenoid CDDO-Imidazolide, and STAT phosphorylation and apoptosis were evaluated by immunoblotting and fluorescence-activated cell sorting analysis.

Results: We now report that CDDO-Imidazolide, previously shown to be a potent agent for control of inflammation, cell proliferation, and apoptosis, rapidly (within 30-60 minutes) and potently (at nanomolar levels) suppresses either constitutive or interleukin-6-induced STAT3 and STAT5 phosphorylation in human myeloma and lung cancer cells. Furthermore, in these cells, CDDO-Imidazolide also up-regulates critical inhibitors of STATs, such as suppressor of cytokine signaling-1 and SH2-containing phosphatase-1 (a tyrosine phosphatase). Moreover, gene array studies reported here show that CDDO-Imidazolide potently regulates the transcription of important genes that are targets of the STATs.

Conclusions: Our new data thus show that CDDO-Imidazolide is a potent suppressor of STAT signaling and provide a further mechanistic basis for future clinical use of this agent to control inflammation or cell proliferation.




This article has been cited by other articles:


Home page
Clin. Cancer Res.Home page
K. Liby, R. Risingsong, D. B. Royce, C. R. Williams, M. M. Yore, T. Honda, G. W. Gribble, W. W. Lamph, N. Vannini, I. Sogno, et al.
Prevention and Treatment of Experimental Estrogen Receptor-Negative Mammary Carcinogenesis by the Synthetic Triterpenoid CDDO-Methyl Ester and the Rexinoid LG100268
Clin. Cancer Res., July 15, 2008; 14(14): 4556 - 4563.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
R. Ahmad, D. Raina, C. Meyer, and D. Kufe
Triterpenoid CDDO-Methyl Ester Inhibits the Janus-Activated Kinase-1 (JAK1)->Signal Transducer and Activator of Transcription-3 (STAT3) Pathway by Direct Inhibition of JAK1 and STAT3
Cancer Res., April 15, 2008; 68(8): 2920 - 2926.
[Abstract] [Full Text] [PDF]


Home page
Molecular Cancer TherapeuticsHome page
N. Vannini, G. Lorusso, R. Cammarota, M. Barberis, D. M. Noonan, M. B. Sporn, and A. Albini
The synthetic oleanane triterpenoid, CDDO-methyl ester, is a potent antiangiogenic agent
Mol. Cancer Ther., December 1, 2007; 6(12): 3139 - 3146.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
K. Liby, D. B. Royce, R. Risingsong, C. R. Williams, M. D. Wood, R. A. Chandraratna, and M. B. Sporn
A New Rexinoid, NRX194204, Prevents Carcinogenesis in Both the Lung and Mammary Gland
Clin. Cancer Res., October 15, 2007; 13(20): 6237 - 6243.
[Abstract] [Full Text] [PDF]


Home page
Mol Cancer ResHome page
A. K. Pathak, M. Bhutani, A. S. Nair, K. S. Ahn, A. Chakraborty, H. Kadara, S. Guha, G. Sethi, and B. B. Aggarwal
Ursolic Acid Inhibits STAT3 Activation Pathway Leading to Suppression of Proliferation and Chemosensitization of Human Multiple Myeloma Cells
Mol. Cancer Res., September 1, 2007; 5(9): 943 - 955.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
A. Albini, D. M. Noonan, and N. Ferrari
Molecular Pathways for Cancer Angioprevention
Clin. Cancer Res., August 1, 2007; 13(15): 4320 - 4325.
[Abstract] [Full Text] [PDF]


Home page
Molecular Cancer TherapeuticsHome page
K. Liby, T. Honda, C. R. Williams, R. Risingsong, D. B. Royce, N. Suh, A. T. Dinkova-Kostova, K. K. Stephenson, P. Talalay, C. Sundararajan, et al.
Novel semisynthetic analogues of betulinic acid with diverse cytoprotective, antiproliferative, and proapoptotic activities
Mol. Cancer Ther., July 1, 2007; 6(7): 2113 - 2119.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
K. Liby, D. B. Royce, C. R. Williams, R. Risingsong, M. M. Yore, T. Honda, G. W. Gribble, E. Dmitrovsky, T. A. Sporn, and M. B. Sporn
The Synthetic Triterpenoids CDDO-Methyl Ester and CDDO-Ethyl Amide Prevent Lung Cancer Induced by Vinyl Carbamate in A/J Mice
Cancer Res., March 15, 2007; 67(6): 2414 - 2419.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Cell Physiol.Home page
V. Contreras-Shannon, O. Ochoa, S. M. Reyes-Reyna, D. Sun, J. E. Michalek, W. A. Kuziel, L. M. McManus, and P. K. Shireman
Fat accumulation with altered inflammation and regeneration in skeletal muscle of CCR2-/- mice following ischemic injury
Am J Physiol Cell Physiol, February 1, 2007; 292(2): C953 - C967.
[Abstract] [Full Text] [PDF]


Home page
Molecular Cancer TherapeuticsHome page
M. M. Yore, K. T. Liby, T. Honda, G. W. Gribble, and M. B. Sporn
The synthetic triterpenoid 1-[2-cyano-3,12-dioxooleana-1,9(11)-dien-28-oyl]imidazole blocks nuclear factor-{kappa}B activation through direct inhibition of I{kappa}B kinase {beta}
Mol. Cancer Ther., December 1, 2006; 5(12): 3232 - 3239.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 2006 by the American Association for Cancer Research.